A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
NeoImmuneTech
National Institutes of Health Clinical Center (CC)
Essen Biotech
Eli Lilly and Company
Merck Sharp & Dohme LLC
Maastricht University Medical Center
Eli Lilly and Company
Bicara Therapeutics
Carisma Therapeutics Inc
Eli Lilly and Company
Astellas Pharma Inc
NGM Biopharmaceuticals, Inc
ENB Therapeutics, Inc
ADC Therapeutics S.A.
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Corvus Pharmaceuticals, Inc.
Fate Therapeutics
Kineta Inc.
M.D. Anderson Cancer Center
Fate Therapeutics
Xencor, Inc.
Incyte Corporation